Home
Overview
Advisory board
Institutional Review Board (IRB)
MCOG | Aswan 2023
Clinical studies
Practice guidelines
MCOG/MOGGE clinical courses
Community campaigns
Artificial intelliegence (AI) unit
MOGGEsoft
SilverAxon Inc.
MOGGE books
Research fellowship
Board of directors (BOD)
Patient education
Educational resources
Team
More
Primary outcome of the study will be cancer-specific survival (CSS) rate at 3 and 5
years after initiation of treatment. Recurrence-free survival (RFS) rate at 3 and 5 years constitutes the secondary outcome
4/11-5/12